4DMedical secures $10mstrategic invest' from Pro Medicus
Filed with ASX · · 3 pages · English
Summary by 6ix AI
This investment will help accelerate the commercial pipeline for existing products and advance the CT:VQ™ technology towards regulatory clearance in the U.S. The agreement is structured as a hybrid debt and equity loan, providing non-dilutive options under certain conditions.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Earlier from 4DMedical
- 4DMedical renews 3 year contract with University of Michigan
- Lung Scan Technology Reveals Hidden Secrets of Airway Disease
- 4DMedical contract with Stanford, includes CTVQ
- Olympus launches new SeleCT Screening campaign
- Investor Presentation - FDA Submission for CTVQ
Later from 4DMedical
- Appendix 4E - Preliminary Final Report
- FY2025 Full year results
- 4DMedical receives FDA clearance for CTVQ
- 4DMedical receives $6.0m R&D Tax Incentive
- 4DMedical gains U.S. CMS reimbursement for CTVQ
Follow 4DMedical into a list and get an email when it puts out news.
Follow 4DMedical